Follow on Google News
News By Tag
News By Place
Follow on Google News
A Combination of Ramucirumab Plus Pembrolizumab Lengthened Survival For Some Lung Cancer Patients
By: Hunan Huateng Pharmaceutical Co. Ltd.
The study, also known as S1800A, a division of the National Institutes of Health (NIH), and conducted at NCI's National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP).
Pembrolizumab is a class of immunotherapy drugs called immune checkpoint inhibitors (ICIs), while ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, a class of drugs that block the enzyme drug.
The randomized phase 2 S1800A study enrolled 136 eligible patients with stage IV or recurrent non-small cell lung cancer. These patients had previously received ICI therapy. In all cases, the patients' tumors eventually became resistant to these drugs and grew or spread before the patients were enrolled in the S1800A trial.
The trial rapidly accumulated and had a diverse population, in large part because of the strong rollout of the Lung-MAP primary screening protocol. Roy S. Herbst, MD, associate director of the Yale Cancer Center, founder and principal investigator of Lung-MAP, and senior author of the paper, commented, "The unique nature of the Lung-MAP public-private partnership, the breadth and breadth of NCI's NCTN and NCORP, Backed by the diverse nature, we are able to bring these new treatments to patients with advanced lung cancer nationwide at no cost—an important improvement in patient access."
Overall survival was the primary endpoint of the trial. Secondary endpoints included progression-
Treatment-related adverse events (side effects) of grade 3 or higher occurred in 42% of patients in the ramucirumab plus pembrolizumab group and 60% of those in the standard-of-
Treatment in the trial control group was chosen by physicians and patients from a group of four standard chemotherapy regimens: docetaxel plus ramucirumab, docetaxel alone, gemcitabine or pemetrexed. About two-thirds of patients receiving standard care received docetaxel and ramucirumab as the most aggressive treatments approved in this setting.
Huateng Pharma, as a leading pharmaceutical intermediates (https://us.huatengsci.com/
Account Email Address Account Phone Number Disclaimer Report Abuse